2017 Taiwan lipid guidelines for high risk patients
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and familial hypercholesterolemia (FH), lipid control is also necessary in these patients. Lifestyle modification is the first step to control lipid. Weight reduction, regular physical exercise and limitation of alcohol intake all reduce triglyceride (TG) levels. Lipid-lowering drugs include HMG-CoA reductase inhibitors (statins), cholesterol absorption inhibitors (ezetimibe), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, nicotinic acids (niacin), fibric acids derivatives (fibrates), and long-chain omega-3 fatty acids. Statin is usually the first line therapy. Combination therapy with statin and other lipid-lowering agents may be considered in some clinical settings. For patients with acute coronary syndrome (ACS) and stable CAD, LDL-C < 70 mg/dL is the major target. A lower target of LDL-C <55 mg/dL can be considered in ACS patients with DM. After treating LDL-C to target, non-HDL-C can be considered as a secondary target for patients with TG ≥ 200 mg/dL. The suggested non-HDL-C target is < 100 mg/dL in ACS and CAD patients. For patients with ischemic stroke or transient ischemic attack presumed to be of atherosclerotic origin, statin therapy is beneficial and LDL-C < 100 mg/dL is the suggested target. For patients with symptomatic carotid stenosis or intracranial arterial stenosis, in addition to antiplatelets and blood pressure control, LDL-C should be lowered to < 100 mg/dL. Statin is necessary for DM patients with CV disease and the LDL-C target is < 70 mg/dL. For diabetic patients who are ≥ 40 years of age, or who are < 40 years of age but have additional CV risk factors, the LDL-C target should be < 100 mg/dL. After achieving LDL-C target, combination of other lipid-lowering agents with statin is reasonable to attain TG < 150 mg/dL and HDL-C >40 in men and >50 mg/dL in women in DM. LDL-C increased CV risk in patients with CKD. In adults with glomerular filtration rate (GFR) < 60 mL/min/1.73m2 without chronic dialysis (CKD stage 3–5), statin therapy should be initiated if LDL-C ≥ 100 mg/dL. Ezetimibe can be added to statin to consolidate the CV protection in CKD patients. Mutations in LDL receptor, apolipoprotein B and PCSK9 genes are the common causes of FH. Diagnosis of FH usually depends on family history, clinical history of premature CAD, physical findings of xanthoma or corneal arcus and high levels of LDL-C. In addition to conventional lipid lowering therapies, adjunctive treatment with mipomersen, lomitapide, or PCSK9 inhibitors become necessary to further reduce LDL-C in patients with FH. Overall, these recommendations are to help the health care professionals in Taiwan to treat hyperlipidemia with current scientific evidences. We hope the prescription rate of lipid lowering drugs and control rate of hyperlipidemia in high risk patients could be increased by implementation of the clinical guidelines. The major purpose is to improve clinical outcomes of these high risk patients through the control of hyperlipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Mensink, R. P., Zock, P. L., Kester, A. D., & Katan, M. B. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.5.1146 · Cited by 2,811
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Predictors of New-Onset Kidney Disease in a Community-Based Population
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.291.7.844 · Cited by 1,241
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Nordmann, A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S., Brehm, B. J., & Bucher, H. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.285 · Cited by 973
Exercise for overweight or obesity
Shaw, K. A., Gennat, H. C., O'Rourke, P., & Del Mar, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003817.pub3 · Cited by 950
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
Wood, P. D., Stefanick, M. L., Dreon, D. M., Frey-Hewitt, B., Garay, S. C., Williams, P. T., Superko, H. R., Fortmann, S. P., Albers, J. J., Vranizan, K. M., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811033191801 · Cited by 675
Levitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668
Health effects of trans-fatty acids: experimental and observational evidence
Mozaffarian, D., Aro, A., & Willett, W. C. (2009) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602973 · Cited by 662
Amarenco, P., & Labreuche, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70058-4 · Cited by 660
Sacks, F. M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P., & Winston, M. (2006) · Circulation · doi:10.1161/circulationaha.106.171052 · Cited by 656
Components of a Cardioprotective Diet: New Insights
Mozaffarian, D., Appel, L. J., & Van Horn, L. (2011) · Circulation · doi:10.1161/circulationaha.110.968735 · Cited by 571
Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 513
McCane, D. R., Hanson, R. L., Charles, M. A., Jacobsson, L. T. H., Pettitt, D. D., Bennett, P. H., & Knowler, W. C. (1994) · BMJ · doi:10.1136/bmj.308.6940.1323 · Cited by 484
Nicholls, S. J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., Uno, K., Tuzcu, E. M., & Nissen, S. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.026 · Cited by 475
Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., Komura, N., Sakamoto, K., Oka, H., Nakao, K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.065 · Cited by 459
Cholesterol and the risk of renal dysfunction in apparently healthy men
Schaeffner, E. S., Kurth, T., Curhan, G. C., Glynn, R. J., Rexrode, K. M., Baigent, C., Buring, J. E., & Gaziano, J. M. (2003) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1482084 · Cited by 442
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region.
Asia Pacific Cohort Studies Collaboration (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg106 · Cited by 382
Engelgau, M. M., Thompson, T. J., Herman, W. H., Boyle, J. P., Aubert, R. E., Kenny, S. J., Badran, A., Sous, E. S., & Ali, M. A. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.785 · Cited by 325
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.072 · Cited by 302
Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis
Eslick, G. D., Howe, P. R. C., Smith, C., Priest, R., & Bensoussan, A. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.03.092 · Cited by 299
Shin, J. Y., Xun, P., Nakamura, Y., & He, K. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.051318 · Cited by 289
Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272
Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes
Hu, G., Jousilahti, P., Barengo, N. C., Qiao, Q., Lakka, T. A., & Tuomilehto, J. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.799 · Cited by 265
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
Imamura, T., Doi, Y., Arima, H., Yonemoto, K., Hata, J., Kubo, M., Tanizaki, Y., Ibayashi, S., Iida, M., & Kiyohara, Y. (2009) · Stroke · doi:10.1161/strokeaha.108.529537 · Cited by 235
Kastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233
Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2453 · Cited by 226
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Lipids and Cerebrovascular Disease: Research and Practice
Yaghi, S., & Elkind, M. S. V. (2015) · Stroke · doi:10.1161/strokeaha.115.011164 · Cited by 176
Gerards, M. C., Terlou, R. J., Yu, H., Koks, C. H. W., & Gerdes, V. E. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.004 · Cited by 169
Fibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142
Navarese, E. P., Kowalewski, M., Andreotti, F., van Wely, M., Camaro, C., Kolodziejczak, M., Gorny, B., Wirianta, J., Kubica, J., Kelm, M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.02.034 · Cited by 130
Nagasawa, S., Okamura, T., Iso, H., Tamakoshi, A., Yamada, M., Watanabe, M., Murakami, Y., Miura, K., Ueshima, H., & for the Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH‐JAPAN) Research Group (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001974 · Cited by 101
Huang, Y., Li, W., Dong, L., Li, R., & Wu, Y. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14001 · Cited by 76
Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis
Rabkin, S. W. (1984) · Atherosclerosis · doi:10.1016/0021-9150(84)90193-x · Cited by 43
Cited by
Community, R. O. T. G. F. H., Wilemon, K. A., Patel, J., Aguilar-Salinas, C., Ahmed, C. D., Alkhnifsawi, M., Almahmeed, W., Alonso, R., Al-Rasadi, K., Badimon, L., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.5173 · Cited by 256
Chang, C.-H., Tseng, P.-T., Chen, N.-Y., Lin, P.-C., Lin, P.-Y., Chang, J. P. C., Kuo, F.-Y., Lin, J., Wu, M.-C., & Su, K.-P. (2018) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.01.001 · Cited by 103
Kuo, P.-H., Sun, H.-Y., Chuang, Y.-C., Wu, P.-Y., Liu, W.-C., & Hung, C.-C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.12.029 · Cited by 61
Efficacy and Safety of Inclisiran in Asian Patients
Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2023.09.006 · Cited by 31
Self-citation
Metadata
- Authors
- Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., Chien, S.-C., Liou, C.-W., Tang, S.-C., Lee, C.-C., Yu, T.-Y., Chen, J.-W., Wu, C.-C., & Yeh, H.-I.
- Venue
- Journal of the Formosan Medical Association
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 116
- Issue
- 4
- Pages
- 217-248
- ISSN
- 0929-6646 (ISSN-L)
- OpenAlex
- W2591240813
- Cited by
- 157
- References
- 77
- FWCI
- 17.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.